Zalutumumab
drugOn this page
Also known as 2F8HUMAX-EGFR, 2F8HUMAX-EGFR-2F8HuMax-EGFr
Summary
Zalutumumab (CHEMBL2107861) is a phase-3 clinical-stage antibody; indicated across 5 conditions including upper aerodigestive tract neoplasm and squamous cell carcinoma.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Antibody
- Indications: 5 conditions
- Clinical trials: 10
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2107861 |
| Name | Zalutumumab |
| Type | Antibody |
| Max phase | 3 |
Also known as: 2F8, HUMAX-EGFR, 2F8, HUMAX-EGFR-2F8, HuMax-EGFr, Zalutumumab, ZALUTUMUMAB
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
5 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| upper aerodigestive tract neoplasm | 3 | MONDO:0005398 | EFO:0004284 |
| squamous cell carcinoma | 3 | MONDO:0005096 | EFO:0000707 |
| head and neck cancer | 3 | MONDO:0005627 | EFO:0006859 |
| non-small cell lung carcinoma | 2 | MONDO:0005233 | EFO:0003060 |
| colorectal neoplasm | 1 | MONDO:0005335 | MONDO:0005575 |
Clinical trials
Total trials: 10.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE1/PHASE2 | 5 |
| PHASE2 | 3 |
| PHASE3 | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00382031 | PHASE3 | COMPLETED | Zalutumumab in Patients With Non-curable Head and Neck Cancer |
| NCT00496652 | PHASE3 | COMPLETED | DAHANCA 19: The Importance of the EGFr-inhibitor Zalutumumab for the Outcome After Curative Radiotherapy for HNSCC |
| NCT00093041 | PHASE1/PHASE2 | COMPLETED | Zalutumumab in Head and Neck Cancer |
| NCT00401401 | PHASE1/PHASE2 | TERMINATED | Zalutumumab in Combination With Chemotherapy and Radiotherapy in Head and Neck Cancer |
| NCT00460551 | PHASE2 | TERMINATED | Zalutumumab in Combination With Chemo-Radiation in a Certain Type of Lung Cancer |
| NCT00542308 | PHASE2 | COMPLETED | Zalutumumab in Non-curable Patients With SCCHN |
| NCT00677924 | PHASE1/PHASE2 | TERMINATED | Zalutumumab With or Without Irinotecan Chemotherapy in Cetuximab-Refractory Colorectal Cancer |
| NCT00707655 | PHASE1/PHASE2 | TERMINATED | Zalutumumab in Combination With Radiotherapy in Head and Neck Cancer Patients Ineligible for Platinum Based Chemotherapy |
| NCT01054625 | PHASE1/PHASE2 | COMPLETED | Zalutumumab Pharmacokinetics (PK) in Squamous Cell Carcinoma of the Head and Neck (SCCHN) |
| NCT01449357 | PHASE2 | WITHDRAWN | Zalutumumab in Non-Small Cell Lung Cancer (NSCLC) Patients Refractory to Tyrosine Kinase Inhibitors |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).